Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 1 - 50 of 2930 results
- Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
- Substance-P-mediated immunomodulation of tumor growth in a murine model.
- Cutaneous side-effects of kinase inhibitors and blocking antibodies.
- Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
- Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.
- Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.
- Randomized phase II designs in cancer clinical trials: current status and future directions.
- Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication.
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
- alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.
- Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
- The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
- Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
- Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
- Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
- Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
- In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
- Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk.
- Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
- Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
- Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
- Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.
- A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy.
- Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.
- Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis.
- Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis.
- Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
- Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
- Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
- Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
- Cancer prevention with semi-allogeneic ES cell-derived dendritic cells.
- A replication-selective adenoviral vector for head and neck cancers.
- Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
- A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.
- The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model.
- Carbohydrate vaccines as immunotherapy for cancer.
- Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.
- Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
- Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
- Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
- The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
- A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
- Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
- Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
- Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
- Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.
- Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.
- A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.
- Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8.
- Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.